Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of light-activated small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which research, develops, manufactures and distributes cool laser therapy (CLT) systems to healthcare practitioners, predominantly for the healing of pain.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Your investment in TLD-1433 has been derisked.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1504)
•••
Post by wildbird1on Dec 30, 2024 9:43am
342 Views
Post# 36380636

Your investment in TLD-1433 has been derisked.

Your investment in TLD-1433 has been derisked.My preferred post in 2024, is definitively Eoganacht  '' Latest TLD-1433 shout out''

TSXV:TLT Forum Post | Eoganacht-36360656 | Latest TLD1433 shout-out | Theralase Technologies Inc.
I love this post.

-Many time before, scientists have made positive comments on TLD-1433 potential, but for the very first time ever, a team of highly qualified PHD  scientists completely independent from TLT, are acknowledging that TLD-1433 is a success.

- If they could, what would these PHD scientists say to present and future TLT investors.
To present investors.
In 2025 hold on to your precious TLT shares, TLT will change the way many cancers are treated.

To future investors.
Don't stay to long on the side line, our latest independent studies(Nov, 2024) is derisking drastically the risk of investing in TLT-1433.
Maybe it is time to get on board.

Note: These highly qualified PHD scientists, derisking TLD-1433 is a pleasant feeling.

To a bright and hopeful new year, and may all your TLT dreams come true.

For the last time in 2024....

I love my TLT shares.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities